Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities researchers at Oppenheimer Holdings cut their Q1 2018 EPS estimates for shares of Vanda Pharmaceuticals in a research note issued to investors on Sunday. Oppenheimer Holdings analyst D. Archila now forecasts that the biopharmaceutical company will post earnings of ($0.17) per share for the quarter, down from their prior forecast of ($0.15). Oppenheimer Holdings currently has a “Buy” rating and a $26.00 price target on the stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ FY2018 earnings at ($0.16) EPS, FY2020 earnings at $0.93 EPS and FY2021 earnings at $1.58 EPS.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The company had revenue of $42.06 million for the quarter, compared to analyst estimates of $40.31 million. During the same period last year, the company earned $0.01 earnings per share. The business’s revenue was up 16.7% compared to the same quarter last year. ILLEGAL ACTIVITY WARNING: “Q1 2018 EPS Estimates for Vanda Pharmaceuticals Inc. Lowered by Analyst (VNDA)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/11/01/q1-2018-eps-estimates-for-vanda-pharmaceuticals-inc-lowered-by-analyst-vnda.html.
Several other equities research analysts have also recently commented on VNDA. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 18th. HC Wainwright set a $18.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Piper Jaffray Companies set a $23.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. BidaskClub cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. Vanda Pharmaceuticals has an average rating of “Buy” and an average price target of $22.00.
Vanda Pharmaceuticals (NASDAQ:VNDA) traded down 2.707% during trading on Wednesday, reaching $15.275. The company’s stock had a trading volume of 124,334 shares. Vanda Pharmaceuticals has a 52 week low of $12.70 and a 52 week high of $18.99. The company’s 50 day moving average price is $17.00 and its 200 day moving average price is $15.81. The company’s market cap is $685.21 million.
Hedge funds have recently modified their holdings of the company. Legal & General Group Plc raised its holdings in shares of Vanda Pharmaceuticals by 37.4% in the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 3,022 shares during the period. Kopp Investment Advisors LLC bought a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter valued at about $196,000. Voya Investment Management LLC raised its holdings in shares of Vanda Pharmaceuticals by 29.7% in the 2nd quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 4,605 shares during the period. Dynamic Technology Lab Private Ltd raised its holdings in shares of Vanda Pharmaceuticals by 46.3% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 20,510 shares of the biopharmaceutical company’s stock valued at $335,000 after purchasing an additional 6,487 shares during the period. Finally, American International Group Inc. raised its holdings in shares of Vanda Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after purchasing an additional 1,491 shares during the period. 86.52% of the stock is currently owned by institutional investors.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
What are top analysts saying about Vanda Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vanda Pharmaceuticals Inc. and related companies.